Janus Henderson Group
APRE icon

Janus Henderson Group’s Aprea Therapeutics APRE Stock Holding History

Janus Henderson Group’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-42,559
Closed -$20.5M – 1384
2020
Q3 		$20.5M Sell
42,559
-4,671
-10% -$2.61M 0.01% 703
2020
Q2 		$36.6M Sell
47,230
-13,980
-23% -$9.17M 0.02% 566
2020
Q1 		$41.7M Sell
61,210
-29,333
-32% -$21.5M 0.03% 499
2019
Q4 		$81M Buy
+90,543
New +$49.9M 0.04% 441

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Janus Henderson Group's APRE Position: Q4 2020 in Review

Janus Henderson Group sold out of Aprea Therapeutics (APRE) in Q4 2020, closing a stake of 42,559 shares — an estimated $20.5M sold.

Janus Henderson Group first reported a position in APRE in Q4 2019 and held it in 4 quarters. The position peaked at $81M in Q4 2019. 66 funds tracked by Wall St. Rank hold APRE as of Q4 2020.

  • Janus Henderson Group reported no remaining Aprea Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Janus Henderson Group sold 42,559 Aprea Therapeutics shares in Q4 2020, an estimated $20.5M.
  • Janus Henderson Group first reported a position in Aprea Therapeutics in Q4 2019 and held it in 4 quarters.
  • Janus Henderson Group's Aprea Therapeutics position peaked at $81M in Q4 2019.
  • 66 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2020.

Based on Janus Henderson Group's 13F filing for Q4 2020, filed 16 Feb 2021.